Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MYOCIT – Baricitinib for new-onset juvenile dermatomyositis
2024-513651-32-00Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2022
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of baricitinib in juvenile dermatomyositis (JDM), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: PRINTO 20 level of improvement at week 24. Started Nov 2022; status: completed.
02
Drugs
baricitinib
03
Conditions
juvenile dermatomyositis (JDM)
Beyond the preview
Go deeper on 2024-513651-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513651-32-00.